More Otsuka Holdings Co., Ltd. news
Otsuka Holdings Co., Ltd.TSE: 4578

Notice Regarding Transition to a Company with an Audit and Supervisory Committee

Oct 30, 2026 at 12:30 AM EDT · Issued by Otsuka Holdings Co., Ltd. via TDnet

Filed with TSE · Oct 30, 2026 at 12:30 AM EDT · 1 page · English

On 6ix: 6ix.com/news/notice-regarding-transition-to-a-company-with-an-audit-and-supervisory-committee

Otsuka Holdings Co., Ltd. on 6ix

Earlier from Otsuka

  • Otsuka Presents Final Phase 3 VISIONARY Results for VOYXACT at ASNOct 22
  • Otsuka Completes Rolling Submission of Supplemental Biologics License Application (sBLA) for Traditional Approval of VOYXACT in U.S.Oct 7
  • NDA Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA RTOR ProgramOct 1
  • Notice regarding the status of share repurchasesOct 1
  • Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted TreatmentSep 22

Later from Otsuka

  • New Drug Application Submission Completed for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung CancerNov 12
All Otsuka news releases↗

Follow Otsuka into a list and get an email when it puts out news.

Follow Otsuka
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer